27 Oct 2026, 06:56 IST
Mankind Pharma Limited
HDFC Securities · ADD · target INR 2,610
The report says EBITDA grew 27% YoY on 17% sales growth and margin expansion, with India formulation expected to outperform IPM in H2FY27 and margin guidance of 25.5-26.5% retained, with the TP revised to INR 2,610.
From HSIE Results Daily 27 Oct 26 HSIE, written by HDFC Securities. Orivam summarised it; the view is HDFC Securities's, not Orivam's.
Open the original PDF →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.